New hope for tough ovarian cancer: HS-20089 takes on chemo in major trial
NCT ID NCT06855069
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called HS-20089 against standard chemotherapy for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 468 participants will be randomly assigned to receive either HS-20089 or a standard chemo chosen by their doctor. The main goal is to see if HS-20089 can delay cancer growth longer than standard chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China